



5 July 2019

ASX ANNOUNCEMENT

Dispatch of Entitlement Offer Booklet and Entitlement & Acceptance Form

Brisbane, Australia and Carlsbad, California. – ImpediMed Limited (ASX:IPD) announces that it has today dispatched the Entitlement Offer Booklet and personalised Entitlement and Acceptance form to shareholders who are eligible to participate in the Entitlement Offer announced on Thursday, 27 June 2019.

The Entitlement Offer is now open for acceptance by Eligible Shareholders (defined below). It is currently scheduled to close at 5.00pm (AEST) on 5.00pm (AEST) on Tuesday, 16 July 2019.

Entitlement Offer Booklet

A copy of the Entitlement Offer Booklet has been released on the ASX announcements platform today. The Entitlement Offer Booklet contains information for Eligible Shareholders (defined below) in relation to the Entitlement Offer.

Eligible Shareholders who wish to participate in the Entitlement Offer are encouraged to read the Offer Booklet carefully before applying, including the risks related to ImpediMed and the risks of investing in ImpediMed shares. Participation in the Entitlement Offer is entirely voluntary. If an Eligible Shareholder is unsure of what action to take, they should consult their financial or other professional adviser.

Eligible shareholders

The Entitlement Offer is being made to those Shareholders who are:

- registered as a holder of ImpediMed's Shares as at 7.00pm AEST on Tuesday, 2 July 2019;
- have a registered address in Australia or New Zealand;
- not in the United States, are not a US Person, and are not acting for the account or benefit of any person in the United States or any US Person; and
- eligible under all applicable securities laws to receive an offer under the Entitlement Offer as determined by the Company and the Underwriters.

Shareholders who do not meet the criteria set out above are considered ineligible shareholders and cannot participate in the Entitlement Offer.

How to apply

The Entitlement Offer is currently scheduled to close at **5.00pm (AEST) on Tuesday, 16 July 2019 (Closing Date)**. If you wish to subscribe for New Shares, you must ensure that your Entitlement and Acceptance Form and payment is received by the Closing Date.

Eligible Shareholders may apply by either following the instructions in the Entitlement Offer Booklet and the personalised application form accompanying the Entitlement Offer Booklet (once received through the post) or, in order to expedite and facilitate applications, may apply on-line from today by clicking on the Entitlement Offer website at: <https://events.miraqle.com/IPD-offer>

Eligible Shareholders must pay their application monies in Australian currency only (either by BPAY® through their Australian financial institution or by cheque).

Enquiries on the Entitlement Offer

For further information regarding the Entitlement Offer, please call the Entitlement Offer Information Line on 1300 131 543 (within Australia) and +61 1300 131 543 (from outside Australia) between 8.30am and 5.30pm (AEST) on business days during the offer period for the Entitlement Offer.

ENDS.

Richard Carreon
Managing Director & CEO

Media Contact:
Kyahn Williamson, WE Buchan
T: +61 3 9866 4722
E: kwilliamson@buchanwe.com.au

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.